news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

[industry insiders suggest that local companies should focus on "going global". cell and gene therapy products are relatively expensive, and companies need to cover the population that can afford them in the international market, or when establishing technology and product projects, they should consider whether they can become assets with trading value on a global scale.]

"the reason why the pilot program was opened up to the free trade zones (ports) of beijing, shanghai, guangzhou and hainan is mainly because the cell and gene therapy industries in these regions are developing relatively fast or actively, and they are also key areas for foreign investment. this will have positive significance for the development of cell and gene therapy technology and industry in the pilot areas," said wu zhaohui, vice chairman of the china pharmaceutical biotechnology association, in an interview with caixin.

"the new policy will undoubtedly promote profound changes in the bio-pharmaceutical industry in the free trade zone, and will more effectively promote the implementation of r&d and manufacturing projects of multinational pharmaceutical companies in china, especially the integrated development of chinese and foreign pharmaceutical companies in the free trade zone, taking advantage of the 'bonded +' advantages." said chen yifeng, director of the shanghai food and drug safety research association and deputy general manager of shanghai waigaoqiao international trade operation center co., ltd.

on september 8, the ministry of commerce, the national health commission and the national medical products administration jointly issued the "notice on carrying out pilot work on expanding opening-up in the medical field" (hereinafter referred to as the "notice"). the "notice" pointed out that foreign-invested enterprises are allowed to engage in the development and application of human stem cells, gene diagnosis and treatment technologies in the beijing, shanghai, guangdong free trade zones and hainan free trade port for product registration, listing and production. all products that have been registered, listed and approved for production can be used nationwide.